Open AccessProlonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
Author(s) -
Herman Depypere,
Yanrong Su,
Nhi M. Dang,
Bruce Poppe,
Frank Z. Stanczyk,
Jaak Janssens,
José Russo
Publication year - 2021
Publication title -
european journal of cancer prevention
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.976
H-Index - 77
eISSN - 1473-5709
pISSN - 0959-8278
DOI - 10.1097/cej.0000000000000664
Subject(s) - breast cancer , medicine , pregnancy , human chorionic gonadotropin , brca mutation , hormone , transcriptome , gynecology , biopsy , oncology , andrology , gene , cancer , gene expression , biology , genetics
An early first full-time pregnancy substantially reduces the risk of developing breast cancer later in life. Extensive studies indicate that this protective effect is mediated by the pregnancy hormone human chorionic gonadotrophin (hCG).